Phase 2 Breast Cancer Trial, Recruiting NCT05891561 Sponsor: Shanghai Jiao Tong University School of Medicine Condition: Breast Cancer
Back to Breast Cancer

Phase 2 Breast Cancer Trial, Recruiting

NCT05891561
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have been diagnosed with breast cancer in one breast only, confirmed by laboratory tissue testing, where the cancer is at an early stage and has not spread to the lymph nodes or other parts of the body (classified as pT1, pN0, M0)
  • People whose breast cancer tests positive for a protein called HER2, confirmed by specific laboratory tests following established medical guidelines
  • People whose medical records contain complete diagnosis and treatment information
  • People who are generally well and able to carry out daily activities with little or no difficulty (rated 0 or 1 on a standard health performance scale)
  • People who are not currently pregnant or breastfeeding
  • People whose major organs (such as heart, liver, and kidneys) are functioning well
  • People who are willing to follow the planned treatment schedule, understand what the study involves, and have signed a written consent form

Who may not be able to join:

  • People who have breast cancer in both breasts, or whose cancer has spread to other parts of the body
  • People who are currently receiving treatment given before surgery (neoadjuvant treatment)
  • People who have had another type of cancer within the past 5 years, with the exception of certain already-cured conditions such as early-stage cervical cancer or certain non-serious skin cancers
  • People with serious ongoing infections or other severe illnesses
  • People with HIV infection, or currently active hepatitis B or C infection
  • People with a known allergy or intolerance to the study drug or any of its ingredients
  • People who have previously received chemotherapy, hormone therapy, biological therapy, or radiation therapy for any reason
  • People who have participated in another clinical trial within 4 weeks before the start of this study
  • People who have received a live vaccine within 30 days before the start of this study
  • People with a history of mental illness or substance misuse that may make it difficult to follow the trial requirements
  • People whom the trial researchers determine are not suitable for the study for other reasons (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 15 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: +8621-64370045*602102

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Shanghai Jiao Tong University School of Medicine
Registry
ClinicalTrials.gov
Start date
1 November 2023
Est. completion
1 December 2026

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Disease free survival [DFS]

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 15 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov